PatrĂ­cia Silva, PhD, director of science content —

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Actelion’s Uptravi Now Available in Germany to Treat Pulmonary Arterial Hypertension

Actelion recently announced that its oral drug Uptravi (selexipag) is now commercially available in Germany for the treatment of pulmonary arterial hypertension (PAH). “The availability of Uptravi is a milestone for PAH patients in Germany, where until now, the options for treatments targeting the prostacyclin pathway have been limited, and were burdensome…

#PHAware: Who Are Steve and Lucas Van Wormer?

Steve Van Wormer and Lucas Van Wormer are now among the most prominent faces in the fight against pulmonary hypertension (PH). But who are they? The story of this family is intrinsically marked by an unimaginable turn, the global movement #PHAware, and the chronic disease that is characterized by high…

Galectin-3 Inhibitors Show Positive Preclinical Results for PAH Vascular Remodeling

Galectin Therapeutics recently announced that GR-MD-02, its galectin-3 (gal-3) inhibitor in development-stage, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). Galectin proteins are key mediators of biologic function. The announcement was made during a poster presentation of the company’s preclinical results at…

PH YouTube Star: The Story of Chloe Temtchine

Chloe Temtchine is a celebrity and singer like many others, but she is also a pulmonary hypertension (PH) patient who uses her talent to raise awareness for the disease. The breathing tubes that the singer needs to use while singing became her mark, while her music became an inspiration for patients…

Reviva Presents Positive Results on RP5063 for Pulmonary Arterial Hypertension at ATS 2016

Reviva Pharmaceuticals, Inc. recently presented positive preclinical efficacy results for RP5063 in pulmonary arterial hypertension (PAH) at the American Thoracic Society (ATS) 2016 International Conference, held in San Francisco from May 13-18. RP5063 is a novel atypical antipsychotic drug with a relatively unique pharmacology and a novel target for treating PAH. Its…


A Conversation With Rare Disease Advocates